Results 61 to 70 of about 45,831 (210)

Therapeutic Gene Editing: DNA Repair Pathways, Emerging Editors, and Clinical Progress

iNew Medicine, EarlyView.
ABSTRACT The field of gene editing has evolved rapidly over the past decade, progressing from programmable zinc‐finger nucleases (ZFNs) and transcription activator‐like effector nucleases (TALENs) to the widespread adoption of CRISPR‐Cas systems. First‐generation editors catalyzed genome engineering by introducing targeted double‐strand breaks (DSBs ...
Li‐Kuang Tsai, Youcai Xiong, Dongqi Liu, Dongshan Yang, Jifeng Zhang, Jie Xu, Renzhi Han, Y. Eugene Chen   +7 more
wiley   +1 more source

El cáncer hereditario en mujeres

Arbor: Ciencia, Pensamiento y Cultura, 2015
La mayoría de los casos de cáncer son esporádicos, entre un 20-30% presentan agregación familiar, mientras que solo el 5 -10% son de carácter hereditario.
Rafael Morales Chamorro, Isabel Chirivella González, Gemma Llort Pursals, Ana Beatriz Sánchez Heras, Raquel Serrano Blanch, Alexandre Teule Vega, Carmen Guillén Ponce, Begoña Graña Suárez   +7 more
doaj   +1 more source

Poly(ADP-ribose) Polymerase-1 Down-regulates BRCA2 Expression through the BRCA2 Promoter [PDF]

Journal of Biological Chemistry, 2008
Expression of the BRCA2 tumor suppressor gene is tightly linked to its roles in DNA damage repair and maintenance of chromosomal stability and genomic integrity. Three transcription factors that activate (USF, NF-kappaB, and Elf1) and a single factor that represses (SLUG) BRCA2 promoter activity have been reported. In addition, a 67-bp region (-582 to -
Jinhua, Wang, Chunjing, Bian, Jing, Li, Fergus J, Couch, Kangjian, Wu, Robert Chunhua, Zhao   +5 more
openaire   +2 more sources

Organoids and organ‐on‐a‐chip models for investigating the pathophysiology of the human reproductive system

Interdisciplinary Medicine, EarlyView.
Organoids and organ‐on‐a‐chips are advancing reproductive system research. In the female reproductive system, applications include cancer organoid models, placental chips, and hormone simulation models. For the male reproductive system, research focuses on drug resistance mechanisms, co‐culture platforms, and infertility studies. These refined in vitro
Hongqi Zhang, Shiwen Deng, Fangfang Jin, Jiayao Qu, Xiang Fan, Peng Chen, Xinrong Fan   +6 more
wiley   +1 more source

RISK FACTORS OF OVARIAN CANCER AND POSSIBLE PREVENTIVE STRATEGIES

Фундаментальная и клиническая медицина, 2018
Here we review the current data on prevention, diagnosis, and treatment of ovarian cancer, one of the most prevalent genitourinary cancers characterized by high mortality and case fatality rates due to the lack of efficient screening and treatment ...
OLGA B. Karelina, NATALIA V. Artymuk, TATIANA I. Fetisova   +2 more
doaj  

Should MRI replace mammography as the initial screening modality for asymptomatic women aged 18 – 45 years at high risk of developing breast cancer? A systematic review

Asian Journal of Medical Sciences, 2016
Background: Breast cancer occurs in both men and women, although it is more prevalent among women. Mammography is generally the diagnostic imaging modality of choice, but it is limited in the detection of breast cancer in young women, aged 18-45 years ...
GM Akpaniwo
doaj   +1 more source

Attitudes Toward Prenatal Interventions in the Fanconi Anemia Community

Prenatal Diagnosis, EarlyView.
ABSTRACT Objective In‐utero cell and gene therapies may offer prenatal treatment options for inherited diseases. Preclinical data suggests in‐utero (IU) hematopoietic stem cell transplantation (HSCT) could prevent Fanconi anemia (FA) related bone marrow failure without genotoxic conditioning or immune suppression.
Tony Lum, Catherine Lee, Tippi MacKenzie, Billie Lianoglou, Agnieszka Czechowicz   +4 more
wiley   +1 more source

Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study

Programme Grants for Applied Research, 2016
Background: In the UK, women are invited for 3-yearly mammography screening, through the NHS Breast Screening Programme (NHSBSP), from the ages of 47–50 years to the ages of 69–73 years.
D Gareth Evans, Susan Astley, Paula Stavrinos, Elaine Harkness, Louise S Donnelly, Sarah Dawe, Ian Jacob, Michelle Harvie, Jack Cuzick, Adam Brentnall, Mary Wilson, Fiona Harrison, Katherine Payne, Anthony Howell   +13 more
doaj   +1 more source

Reproductive Decision‐Making Among BRCA1/2 Pathogenic Variants Carriers and Physicians: Attitudes Toward Preimplantation and Prenatal Genetic Testing

Prenatal Diagnosis, EarlyView.
ABSTRACT Objective The objective of this paper is to investigate the knowledge and attitudes of BRCA1/2 pathogenic variant carriers and gynecologists regarding preimplantation genetic tests for monogenic diseases (PGT‐M) and prenatal diagnosis (PND).
Marta D'Alonzo, Silvia Actis, Giulia Lavalle, Simona Suraci, Luca Pace, Valentina Elisabetta Bounous, Annamaria Ferrero   +6 more
wiley   +1 more source

Intelligent nano‐platforms in breast cancer therapy: Current advances and future perspectives

Precision Medical Sciences, EarlyView.
The smart nano platform in breast cancer treatment is designed with advanced nanocarriers, including liposomes, hydrogels, porous nanoparticles, and aptamer‐based systems. These systems are capable of targeted drug release and response to environmental stimuli.
Tina Rahimi, Moluk Aivazi
wiley   +1 more source